Does having taken raloxifene change what a woman could do if she developed LCIS or DCIS?
No. Treatment options for LCIS and DCIS would not change if a woman had been taking raloxifene prior to her diagnosis. For more information on treatment options for LCIS and DCIS, visit NCI’s Web site at: http://www.cancer.gov/cancertopics/pdq/treatment/breast/patient. • How many participants developed a cataract during STAR? In the BCPT, women in the tamoxifen group had a 14 percent increased risk of developing a cataract. During STAR, 739 of 9,736 women in the tamoxifen group developed a cataract compared to 603 of 9,754 women in the raloxifene group. Overall, women taking raloxifene were about 20 percent less likely to develop a cataract compared to women taking tamoxifen. • Did any group of women benefit more from raloxifene than others? No. Raloxifene reduced breast cancer risk regardless of age, race, family history, or other known breast cancer risk factors. • Should postmenopausal women at increased risk of breast cancer take raloxifene or tamoxifen based on these results? Post
